Tocilizumab, also known as atlizumab, is an immunosuppressant, for treating rheumatoid arthritis and a severe form of arthritis in children. On March 23, 2020, Genentech announced that it was approved by the FDA to conduct a randomized, double-blind, placebo-controlled Phase III clinical trial (COVACTA) to evaluate intravenous Actemra® (tocilizumab) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia. https://clinicaltrials.gov/ct2/show/NCT04320615
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.